Melatonin for Hypoxic-Ischemic Encephalopathy
This trial will test whether melatonin, a naturally occurring substance, can help improve outcomes for infants with HIE when used in addition to the standard therapy of induced systemic hypothermia.
- Hypoxic-Ischemic Encephalopathy
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2014 Phase 2 trial • 40 Patients • NCT01114373
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What role does Melatonin play in human physiology, and has this been looked at before?
"There are currently 25 Melatonin trials underway, 4 of which have reached Phase 3. The majority of these clinical trials originate out of Houston, Texas; however, there are 26 total locations running these tests."
Are there any positions available for participants in this clinical trial?
"According to the latest information available on clinicaltrials.gov, this study is still looking for patients to enroll. The first posting was on November 1st, 2016, with the most recent edit happening on May 23rd, 2022."
Has this clinical trial been conducted before?
"There are currently 25 live studies for Melatonin across 13 cities and 9 countries. The initial clinical trial for Melatonin occurred in 2007. The trial, sponsored by Eli Lilly and Company, involved 20 participants and completed its N/A drug approval stage. Since 2007 years, 203 trials have been completed."
How many people total will be participating in this clinical trial?
"The listed clinical trial on clinicaltrials.gov is presently looking for patients to enroll. The details of the study were first posted on November 1st, 2016 and have been edited as recently as May 23rd, 2022. This particular research project is recruiting 70 individuals from 2 locations."